4.6 Article

High Lysyl Oxidase (LOX) in the Non-Malignant Prostate Epithelium Predicts a Poor Outcome in Prostate Cancer Patient Managed by Watchful Waiting

Journal

PLOS ONE
Volume 10, Issue 10, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0140985

Keywords

-

Funding

  1. Swedish Research Council [65X-05935-32-3]
  2. Swedish Cancer Foundation [CAN 2013/327]
  3. Lions Cancer Research Foundation

Ask authors/readers for more resources

Lysyl oxidase (LOX) has been shown to both promote and suppress tumor progression, but its role in prostate cancer is largely unknown. LOX immunoreactivity was scored in prostate tumor epithelium, tumor stroma and in the tumor-adjacent non-malignant prostate epithelium and stroma. LOX scores in tumor and non-malignant prostate tissues were then examined for possible associations with clinical characteristics and survival in a historical cohort of men that were diagnosed with prostate cancer at transurethral resection and followed by watchful waiting. Men with a low LOX score in the non-malignant prostate epithelium had significantly longer cancer specific survival than men with a high score. Furthermore, LOX score in non-malignant prostate epithelium remained prognostic in a multivariable analysis including Gleason score. LOX score in prostate tumor epithelium positively correlated to Gleason score and metastases but was not associated with cancer survival. LOX score in tumor and non-malignant prostate stroma appeared unrelated to these tumor characteristics. In radical prostatectomy specimens, LOX immune-staining corresponded to LOX in-situ hybridization and LOX mRNA levels were found to be similar between tumor and adjacent non-malignant areas, but significantly increased in bone metastases samples. LOX levels both in tumors and in the surrounding tumor-bearing organ are apparently related to prostate cancer aggressiveness.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biochemistry & Molecular Biology

Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge

Wouter Bulten, Kimmo Kartasalo, Po-Hsuan Cameron Chen, Peter Strom, Hans Pinckaers, Kunal Nagpal, Yuannan Cai, David F. Steiner, Hester van Boven, Robert Vink, Christina Hulsbergen-van de Kaa, Jeroen van der Laak, Mahul B. Amin, Andrew J. Evans, Theodorus van der Kwast, Robert Allan, Peter A. Humphrey, Henrik Gronberg, Hemamali Samaratunga, Brett Delahunt, Toyonori Tsuzuki, Tomi Hakkinen, Lars Egevad, Maggie Demkin, Sohier Dane, Fraser Tan, Masi Valkonen, Greg S. Corrado, Lily Peng, Craig H. Mermel, Pekka Ruusuvuori, Geert Litjens, Martin Eklund

Summary: The PANDA challenge is the largest histopathology competition to date, aiming to catalyze the development of reproducible AI algorithms for Gleason grading in prostate cancer. The submitted algorithms achieved pathologist-level performance and their diversity and generalization were validated through cross-continental cohorts.

NATURE MEDICINE (2022)

Article Pathology

Percentage grade 4 tumour predicts outcome for prostate adenocarcinoma in needle biopsies from patients with advanced disease: 10-year data from the TROG 03.04 RADAR trial

B. Delahunt, A. Steigler, C. Atkinson, D. Christie, G. Duchesne, L. Egevad, D. Joseph, D. N. Kenwright, J. Matthews, J. D. Murray, C. Oldmeadow, H. Samaratunga, N. A. Spry, M. C. Thunders, H. Hondermarck, J. W. Denham

Summary: Previous reports have shown that quantifying high tumour grade in prostate cancer patients is of prognostic significance. This study found that the length, percentage, and absolute values of Gleason pattern 4 (GP4) were significantly associated with distant progression of tumour, all-cause mortality, and cancer-specific mortality over a 10-year follow-up period. In addition, these parameters outperformed the division of cases according to Gleason score in terms of prognostic significance.

PATHOLOGY (2022)

Article Endocrinology & Metabolism

Ductal and acinar components of mixed prostatic adenocarcinoma frequently have a common clonal origin

Claes Lindh, Hemamali Samaratunga, Brett Delahunt, Rebecka Bergstrom, Venkatesh Chellappa, John Yaxley, Johan Lindberg, Lars Egevad

Summary: Most ductal and acinar prostate adenocarcinoma components of mixed tumors share the same clonal origin. Ductal adenocarcinoma components often exhibit genome doubling events leading to aneuploidy, consistent with the aggressive nature of high grade prostate cancer.

PROSTATE (2022)

Article Radiology, Nuclear Medicine & Medical Imaging

Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy

Matthew J. Roberts, Andrew Morton, Nathan Papa, Anthony Franklin, Sheliyan Raveenthiran, William J. Yaxley, Geoffrey Coughlin, Troy Gianduzzo, Boon Kua, Louise McEwan, David Wong, Brett Delahunt, Lars Egevad, Hemamali Samaratunga, Nicholas Brown, Robert Parkinson, Louise Emmett, John W. Yaxley

Summary: PSMA intensity on PSMA PET/CT is a clinically significant biomarker for predicting oncological outcomes and biochemical recurrence-free survival in patients undergoing radical prostatectomy.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

Article Urology & Nephrology

Findings in 1,123 Men with Preoperative 68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography and Multiparametric Magnetic Resonance Imaging Compared to Totally Embedded Radical Prostatectomy Histopathology: Implications for the Diagnosis and Management of Prostate Cancer

S. Raveenthiran, W. J. Yaxley, T. Franklin, G. Coughlin, M. Roberts, T. Gianduzzo, B. Kua, H. Samaratunga, B. Delahunt, L. Egevad, D. Wong, L. McEwan, N. Brown, R. Parkinson, R. Esler, J. W. Yaxley

Summary: The study aimed to evaluate the ability of mpMRI and PSMA PET/CT individually and in combination to predict tumor location and Gleason score in prostate cancer. The results showed that combining PSMA PET/CT with mpMRI can improve the detection of significant prostate cancer.

JOURNAL OF UROLOGY (2022)

Letter Pathology

Late recurrence of renal solitary fibrous tumour in the contralateral kidney

Hemamal Samaratunga, Tony Gianduzzo, Joanna Perry-Keene, Lars Egevad, Brett Delahunt

PATHOLOGY (2023)

Article Cell Biology

Interobserver reproducibility of cribriform cancer in prostate needle biopsies and validation of International Society of Urological Pathology criteria

Lars Egevad, Brett Delahunt, Kenneth A. Iczkowski, Theo van der Kwast, Geert J. L. H. van Leenders, Katia R. M. Leite, Chin-Chen Pan, Hemamali Samaratunga, Toyonori Tsuzuki, Nita Mulliqi, Xiaoyi Ji, Henrik Olsson, Masi Valkonen, Pekka Ruusuvuori, Martin Eklund, Kimmo Kartasalo

Summary: There is evidence that cribriform morphology is associated with a worse prognosis for prostatic adenocarcinoma. This study aimed to investigate the reproducibility of cribriform cancer diagnosis in prostate needle biopsies. A panel of nine prostate pathology experts independently reviewed 304 digitised biopsies and achieved a 2/3 consensus diagnosis of cribriform and noncribriform cancer in 90% of the cases. Strict diagnostic criteria were used to identify cribriform patterns and generate a set of consensus cases for standardization.

HISTOPATHOLOGY (2023)

Article Multidisciplinary Sciences

Estimating diagnostic uncertainty in artificial intelligence assisted pathology using conformal prediction

Henrik Olsson, Kimmo Kartasalo, Nita Mulliqi, Marco Capuccini, Pekka Ruusuvuori, Hemamali Samaratunga, Brett Delahunt, Cecilia Lindskog, Emiel A. M. Janssen, Anders Blilie, Lars Egevad, Ola Spjuth, Martin Eklund

Summary: This study demonstrates the use of conformal prediction to detect unreliable predictions in the context of prostate biopsy diagnosis and grading. The results show that conformal prediction can improve the accuracy of AI systems and detect systematic differences in external data, highlighting unreliable predictions.

NATURE COMMUNICATIONS (2022)

Article Medicine, General & Internal

Computational pathology in 2030: a Delphi study forecasting the role of AI in pathology within the next decade

M. Alvaro Berbis, David S. McClintock, Andrey Bychkov, Jeroen Van der Laak, Liron Pantanowitz, Jochen K. Lennerz, Jerome Y. Cheng, Brett Delahunt, Lars Egevad, Catarina Eloy, Alton B. Farris III, Filippo Fraggetta, Raimundo Garcia del Moral, Douglas J. Hartman, Markus D. Herrmann, Eva Hollemans, Kenneth A. Iczkowski, Aly Karsan, Mark Kriegsmann, Mohamed E. Salama, John H. Sinard, J. Mark Tuthill, Bethany Williams, Cesar Casado-Sanchez, Victor Sanchez-Turrion, Antonio Luna, Jose Aneiros-Fernandez, Jeanne Shen

Summary: AI is expected to be routinely and impactfully used in pathology practice by 2030, according to experts in the field. This consensus study highlights the anticipated short-to-mid-term impact of AI and raises important practical, ethical, and legal challenges that need to be addressed prior to its clinical implementation.

EBIOMEDICINE (2023)

Article Oncology

Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma

Naveen S. Vasudev, Ghislaine Scelo, Kate I. Glennon, Michelle Wilson, Louis Letourneau, Robert Eveleigh, Nazanin Nourbehesht, Madeleine Arseneault, Antoine Paccard, Lars Egevad, Juris Viksna, Edgars Celms, Sharon M. Jackson, Behnoush Abedi-Ardekani, Anne Y. Warren, Peter J. Selby, Sebastian Trainor, Michael Kimuli, Jon Cartledge, Naeem Soomro, Adebanji Adeyoju, Poulam M. Patel, Magdalena B. Wozniak, Ivana Holcatova, Antonin Brisuda, Vladimir Janout, Estelle Chanudet, David Zaridze, Anush Moukeria, Oxana Shangina, Lenka Foretova, Marie Navratilova, Dana Mates, Viorel Jinga, Ljiljana Bogdanovic, Bozidar Kovacevic, Anne Cambon-Thomsen, Guillaume Bourque, Alvis Brazma, Jorg Tost, Paul Brennan, Mark Lathrop, Yasser Riazalhosseini, Rosamonde E. Banks

Summary: Targeted gene sequencing can help in risk prediction and adjuvant treatment decisions for patients with resected localized ccRCC. Mutations in the VHL gene have a significant impact on patient outcomes, independent of other gene mutations. Genomic characterization can personalize treatment discussions and inform future adjuvant trial design.

CLINICAL CANCER RESEARCH (2023)

Editorial Material Pathology

Tumour grading: communication is the key

Murali Varma, Brett Delahunt, Liang Cheng, Runjan Chetty, Eva Comperat, Vikram Deshpande, Lars Egevad, Theodorus H. van der Kwast, Antonio Lopez-Beltran, W. Glenn McCluggage

JOURNAL OF CLINICAL PATHOLOGY (2023)

Letter Pathology

Not all tumour necrosis is granular necrosis

Hemamali Samaratunga, Lars Egevad, Brett Delahunt

PATHOLOGY (2023)

Review Pathology

Macroscopic examination of pathology specimens: a critical reappraisal

Murali Varma, Laura C. Collins, Runjan Chetty, Dipti M. Karamchandani, Karen Talia, John Dormer, Monika Vyas, Brendan Conn, Yaileen D. Guzman-Arocho, Adam Jones, Miranda Pring, W. Glenn Mccluggage

Summary: This paper highlights the importance of macroscopic examination and tissue sampling in histopathology reporting and discusses potential solutions and challenges. It emphasizes the need for adequate guidance and supervision in macroscopic examination and highlights the importance of clinical context, specimen fixation, macroscopic descriptions, and tissue sampling.

JOURNAL OF CLINICAL PATHOLOGY (2023)

Article Urology & Nephrology

A Novel Radiographic Pattern Related to Poor Prognosis in Patients with Prostate Cancer with Metastatic Spinal Cord Compression

Johan Wanman, Kasim Abul-Kasim, Julius Semenas, Elin Thysell, Anders Bergh, Pernilla Wikstrom, Sead Crnalic

Summary: This study explores the presence and prognostic value of myeloma-like prostate cancer bone metastases and its relation to clinical, molecular, and morphological prognostic markers. The myeloma-like metastatic pattern is associated with poor survival and neurological outcomes after surgery for metastatic spinal cord compression.

EUROPEAN UROLOGY OPEN SCIENCE (2023)

No Data Available